Fortrea (NASDAQ:FTRE) Announces Earnings Results

Fortrea (NASDAQ:FTRE) posted its quarterly earnings results on Thursday. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.22 by $0.06, FiscalAI reports. The business had revenue of $691.50 million for the quarter, compared to analyst estimates of $671.57 million. Fortrea had a positive return on equity of 10.72% and a negative net margin of 3.18%.

Here are the key takeaways from Fortrea’s conference call:

• Fortrea raised and narrowed its 2026 outlook, now expecting revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million, reflecting improved execution and confidence in its return-to-growth strategy.
• Third-quarter adjusted EBITDA rose 14.4% year over year to $58 million, with margin expanding 120 basis points to 8.4% as portfolio mix, cost controls, and efficiency initiatives more than offset higher compensation investments.
• Demand trends improved, with $773 million in net new business awards, a 1.12 times book-to-bill ratio, stronger biotech bookings, and increasing biopharma RFP activity. Management said the broader pipeline and improving market recovery support future growth, although no 2027 guidance was provided.
• Fortrea completed its acquisition of Worldwide Clinical Trials’ Early Phase Services business, expanding its network to more than 570 beds and adding in-house bioanalytical and safety-lab capabilities that management expects to broaden its addressable market and support future profitability.
• Fortrea recorded a cumulative $558 million backlog adjustment, reducing reported backlog to $7.3 billion. Management said the adjustment reflects inactive studies and work no longer expected to be delivered and does not affect current revenue recognition or near- and medium-term planning, but it highlights uncertainty in the long-term backlog.

Fortrea Stock Performance

FTRE traded down $2.30 during trading hours on Friday, hitting $20.84. The company’s stock had a trading volume of 1,516,951 shares, compared to its average volume of 1,555,413. Fortrea has a fifty-two week low of $8.55 and a fifty-two week high of $26.16. The company has a 50-day simple moving average of $20.22 and a 200 day simple moving average of $15.73. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of 1.98. The firm has a market capitalization of $1.98 billion, a PE ratio of -22.99, a PEG ratio of 0.62 and a beta of 1.93.

Analyst Ratings Changes

Several equities research analysts recently commented on FTRE shares. William Blair upgraded shares of Fortrea to a “hold” rating in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft raised Fortrea from a “hold” rating to a “buy” rating and increased their price objective for the stock from $20.00 to $25.00 in a research report on Thursday, October 15th. Zacks Research downgraded Fortrea from a “hold” rating to a “strong sell” rating in a report on Monday, October 12th. UBS Group boosted their target price on Fortrea from $22.00 to $24.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 20th. Finally, Barclays lifted their target price on shares of Fortrea from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $23.23.

Fortrea News Summary

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Barclays raised its price target from $23 to $26 and maintained an “overweight” rating, implying substantial upside from recent trading levels. The upgrade reflects growing confidence in Fortrea’s operating outlook. Barclays Fortrea price-target update
• Positive Sentiment: Fortrea reported third-quarter adjusted earnings of $0.28 per share, exceeding analyst estimates of approximately $0.22-$0.24 and more than doubling the $0.12 reported a year earlier. Revenue of $691.5 million also surpassed the $671.6 million consensus forecast. Fortrea third-quarter earnings beat
• Positive Sentiment: Management raised its 2026 adjusted EBITDA outlook to $210 million-$218 million, signaling stronger expected operating performance and supporting the bullish analyst reaction. Fortrea 2026 EBITDA outlook
• Neutral Sentiment: Fortrea forecast 2026 revenue of $2.665 billion-$2.690 billion. The forecast provides visibility into the company’s expected scale, but investors appear focused more closely on the profitability outlook and the details of the full-year guidance revision. Fortrea third-quarter results
• Negative Sentiment: Shares declined after the earnings release despite the earnings and revenue beats. The reaction suggests investors may have been concerned about the broader guidance revision, Fortrea’s negative net margin, and the need for continued execution before assigning greater value to the stock. Fortrea shares after third-quarter results

Insider Activity at Fortrea

In other Fortrea news, CEO Anshul Thakral sold 99,869 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $19.16, for a total transaction of $1,913,490.04. Following the completion of the transaction, the chief executive officer directly owned 316,797 shares of the company’s stock, valued at approximately $6,069,830.52. This trade represents a 23.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.73% of the stock is owned by corporate insiders.

Fortrea Company Profile

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.